 New York, NY, and Tel Aviv, ISRAEL, Sept. 20, 2021 GLOBE NEWSWIRE -- via NewMediaWire -- Todos Medical, Ltd. OTCQB: TOMDF, a medical diagnostics and solutions company with comprehensive product offerings, today announced it has received a notice of allowance from the US Patent Trademark Office USPTO for a trademark covering the Companys proprietary 3CL protease inhibitor oral antiviral drug candidate NLC-V-01, also known as TollovirTM. In 2020, a Phase 12 clinical study evaluating the safety and efficacy of Tollovir in hospitalized patients was completed by the Companys joint venture partner NLC Pharma Israel, and the Company and NLC are currently enrolling a Phase 2 clinical study in Israel in hospitalized patients. Pivotal Phase 23 clinical studies are currently being planned for both hospitalized and non-hospitalized patients. 